Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial

NEUROBIOLOGY OF AGING

卷:70

Article

Barcelos, Nicole M.^1,2  Van Ness, Peter H.⁵  Wagner, Allison F.^1,2  MacAvoy, Martha G.^1,2  Mecca, Adam P.^1,2  Anderson, George M.⁶  Trentalange, Mark⁵  Hawkins, Keith A.²  Sano, Mary⁷  Arnsten, Amy F. T.³  van Dyck, Christopher H.^1,2,4 

[1] Yale Univ, Sch Med, Alzheimers Dis Res Unit, One Church St,8th Floor, New Haven, CT 06510 USA

[2] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06510 USA

[3] Yale Univ, Sch Med, Dept Neurosci, 333 Cedar St, New Haven, CT 06510 USA

[4] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA

[5] Yale Univ, Sch Med, Dept Med Geriat, 333 Cedar St, New Haven, CT 06510 USA

[6] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA

[7] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA

关键词: Cognitive aging;    Executive function;    Prefrontal cortex;    Brain aging;    Guanfacine;   

DOI  :  10.1016/j.neurobiolaging.2018.05.033

来源: Elsevier

【 摘 要 】

This study evaluated the effect of the alpha-2A-adrenoceptor agonist guanfacine on prefrontally mediated cognitive functions, as well as quality of life and global function in healthy older participants. One hundred twenty-three participants aged 75 years and older were randomly assigned to guanfacine 0.5 mg, 0.1 mg, or placebo daily for 12 weeks. The primary outcome measure was the change in z-score for 6 prefrontal executive function tasks over 12 weeks (PEF6). Neither dose of guanfacine improved PEF6 z-score relative to placebo. The rate of mean change (95% confidence interval) in PEF6 z-score over 12 weeks was 0.270 (0.159, 0.380) for placebo, compared with 0.121 (0.011, 0.232) for guanfacine 0.1 mg (p = 0.06, compared to placebo) and 0.213 (0.101, 0.324) for 0.5 mg (p = 0.47). Neither dose of guanfacine improved the quality of life or global function relative to placebo. Among common adverse events, only dry mouth was significantly more frequent on guanfacine compared to placebo. Guanfacine failed to ameliorate prefrontal cognitive function in older individuals, who were cognitively normal for age. (C) 2018 The Authors. Published by Elsevier Inc.

【 授权许可】

Free